Blackfynn, a life sciences company developing a proprietary data integration and analytics platform to accelerate the development of therapeutics for neurologic disease, has secured two highly competitive direct-to-Phase 2 Small Business Innovation Research (SBIR) grants from the Defense Advanced Research Projects Agency (DARPA) and the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH). The combined grants have the potential to provide approximately $3M in funding to Blackfynn over three years. Blackfynn also announced a collaboration with Ripple, a leading innovator in neural interfaces and medical devices.
The DARPA grant will expand Blackfynn’s capabilities to handle device data with reduced latency, allowing rapid integration and analysis of streaming time-series data from any implanted device or sensor. This has applicability across a wide variety of neuromodulatory devices, including devices to sense and treat seizures, Parkinson’s Disease, depression and others, by sensing, interpreting and modulating neural input to key areas in the brain and peripheral nervous system.
Our work with NIDA will expand the Blackfynn data platform to accelerate translational research in addiction science, focusing on identifying novel combination biomarkers and mechanisms from integrated brain imaging, genomics, neurophysiology and clinical data. This may enable rapid identification of targets, grounded in disease physiology, for drug development.
Under the Ripple collaboration, Blackfynn will extend its proprietary data integration and analysis platform to handle streaming data from Ripple devices, detect relevant events, and adjust device parameters, all in real time. This work builds on the Blackfynn platform’s strong foundational capabilities and will advance our work toward developing closed-loop control of medical devices.
Taken together, the Ripple collaboration and SBIR funding will accelerate the growth of the Blackfynn platform, the expansion of our engineering and scientific teams, and advance applications toward disease modifying therapeutics.
Blackfynn is a technology-driven, life-sciences company dedicated to transforming the way neurological diseases are diagnosed and treated. We combine high-quality patient data, proprietary software, and our multidisciplinary team of domain experts to drive transformational science and the development of effective therapies for the one billion people worldwide who are affected by neurological disease. We partner with pharma and biotech companies, device companies, foundations, government and academic medical centers to achieve this goal. For more information, please visit www.blackfynn.com.